EA for PAAS: A pRCT
NCT04917185 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000
Last updated 2021-06-08
Summary
In 2019, around 27 million people worldwide, corresponding to 0.5% of the adult population, have used amphetamine-type stimulants (ATS). More than one-third of these 27 million users of ATS were in East and South-East Asia. ATS are a group of synthetic psychostimulants including methamphetamine, amphetamine, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and related substances. Although the biology underlying amphetamine withdrawal syndrome is not fully understood, amphetamine has been shown to produce long-lasting reductions in neuronal expression of dopamine neuronal markers. Abuse of these synthetic psychostimulants can lead to drug addiction, and subsequent withdrawal can cause a series of mental symptoms, such as anxiety, depression, confusion, insomnia, mood disturbances, cognitive impairments, and delusions. Some studies have shown two clear stages of ATS withdrawal syndrome: an acute phase lasting 7-10 days, and a subacute phase lasting a further 2 weeks or more, which is termed called "Protracted amphetamine abstinence syndrome (PAAS)".
The relevant literature has indicated that the majority of patients with ATS withdrawal disorders can experience depression, cognitive impairments, insomnia, and anxiety, especially during the PAAS stage. These symptoms may affect the treatment and finally lead to a relapse. Nowadays, pharmacological therapies are mostly symptom-targeted and show an ungratified effectiveness for amphetamine-type drugs. There is no a medication approved by Food and Drug Administration for use in the treatment of methamphetamine addiction. Therefore, the treatment of PAAS is essential for the treatment of ATS use disorders.
Traditional Chinese medicine (TCM), especially acupuncture, is effective in the treatment of withdrawal symptoms with few side effects. research on acupuncture detoxification originates from the treatment of opioid drug withdrawal. Studies have shown that acupuncture has high efficacy in the treatment of protracted abstinence symptoms after heroin addiction. This study hypothesizes that acupuncture has the same mechanism of action in the treatment of PAAS as in the treatment of protracted opioid abstinence syndrome. Therefore, investigators have designed a real-world-based pragmatic randomized controlled trial (pRCT) to determine the effectiveness of acupuncture in the treatment of PAAS and provide support for clinical decision-making.
Investigators conduct a pragmatic randomized controlled trials(pRCT) to observe the effect of acupuncture in a larger sample. It combines the advantages of randomization and real-world data, and the results can provide the best real-world evidence for the assessment of intervention effects or comparative effects.
Conditions
- Substance Withdrawal Syndrome
Interventions
- OTHER
-
Electro-Acupuncture
Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
Sponsors & Collaborators
-
Chengdu University of Traditional Chinese Medicine
lead OTHER
Principal Investigators
-
Yulan Ren, PhD · Chengdu University of Traditional Chinese Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-06-30
- Primary Completion
- 2022-07-31
- Completion
- 2023-12-31
Countries
- China
Study Locations
More Related Trials
-
PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction
NCT02282072 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients
NCT03397212 ·Status: UNKNOWN ·Phase: PHASE4
-
Deep Brain Stimulation of Nucleus Accumbens to Prevent Opiate Relapse
NCT01274988 ·Status: UNKNOWN ·Phase: NA
-
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
NCT01549652 ·Status: COMPLETED ·Phase: NA
-
Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers
NCT00726960 ·Status: UNKNOWN ·Phase: PHASE1
-
Oxytocin Treatment of Opioid Dependence
NCT02548728 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
NCT00980044 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence
NCT02541513 ·Status: UNKNOWN ·Phase: PHASE3
-
Deep Brain Stimulation of Nucleus Accumbens for Opioid Relapse Prevention
NCT03424616 ·Status: UNKNOWN ·Phase: NA
-
Study for Naltrexone on the Abuse Potential of Methylphenidate
NCT03769064 ·Status: COMPLETED ·Phase: PHASE1
-
Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
NCT04075214 ·Status: COMPLETED ·Phase: NA
-
Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
NCT05591703 ·Status: COMPLETED
-
Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence
NCT03015246 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Light Needle for Opioid Use Disorder
NCT05341219 ·Status: UNKNOWN ·Phase: NA
-
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
NCT06233799 ·Status: RECRUITING ·Phase: PHASE3
-
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
NCT04464980 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome
NCT00510016 ·Status: COMPLETED ·Phase: PHASE2
-
Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis
NCT01021566 ·Status: UNKNOWN ·Phase: PHASE3
-
Aprepitant Effects on Oxycodone Response
NCT00999544 ·Status: COMPLETED ·Phase: NA
-
Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland
NCT01100853 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study
NCT01359930 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarkers of Injectable Extended Release Naltrexone Treatment
NCT02324725 ·Status: COMPLETED ·Phase: PHASE4
-
Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
NCT00000353 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenetics of Naltrexone for Stimulant Abuse
NCT03226223 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms
NCT07079215 ·Status: RECRUITING ·Phase: NA